Complex therapy of acute bacterial rinosinusis
https://doi.org/10.21518/2079-701X-2018-8-16-19
Abstract
Federal State Funded Educational Institution of Higher Education I.M. Sechenov First Moscow State Medical University under the Ministry of Health of the Russian Federation (I.M. Sechenov First MSMU) Acute rhinosinusitis is a common disease with worldwide prevalence. It is a disease that leads to the temporary disability and associates with decrease of quality of life. Patients with acute rhinosinusitis seek a medical care not only at otorhinolaryngologist but also to general practitioner, physician and pediatrician of the outpatient departments. Acute bacterial rhinosinusitis (ABRS) usually comes from acute viral upper respiratory infections or acute viral rhinosinusitis. Distinguishing acute viral rhinosinusitis and acute bacterial rhinosinusitis is a frequent challenge to the primary care clinician because of the lack of reliable criteria. So, the diagnosis of acute bacterial rhinosinusitis is most appropriately made on the basis of the medical history, length of the disease and clinical features. The treatment of ABRS should be complex, because despite the infectious etiology of the disease the necessity of antibiotics is still the point at issue. The main required effects of treatment of the acute bacterial rhinosinusitis are anti-inflammatory, mucolytic and anciliary. Phytotherapy is recommended for ABRS treatment by European, American and Russian guidelines.
About the Authors
P. A. Kochetkov
Federal State Funded Educational Institution of Higher Education I.M. Sechenov First Moscow State Medical University under the Ministry of Health of the Russian Federation (I.M. Sechenov First MSMU)
Russian Federation
PhD in medicine
Russian Federation
PhD in medicine
Z. T. Mokoyan
Federal State Funded Educational Institution of Higher Education I.M. Sechenov First Moscow State Medical University under the Ministry of Health of the Russian Federation (I.M. Sechenov First MSMU)
Russian Federation
Russian Federation
References
1. Fokkens WJ, Lund VJ, Mullol J. EPOS 2012: European position paper on rhinosinusitis and nasal polyps. Rhinology, 2012, 50 (1): 1–12.
2. Chow AW, Benninger MS, Brook I. IDSA clinical practice guideline for acute bacterial rhinosinusitis in children and adults. Clin Infect Dis, 2012, 54(8): e72-e112.
3. Anand VK. Epidemiology and economic impact of rhinosinusitis. Ann Otol Rhinol Laryngol Suppl, 2004, 193: 3–5.
4. Kryukov AI, Studenyi ME, Artemiev ME. Treatment of patients with rhinosinusitis: the prospects for conservative and surgical management. Meditsinsky Sovet, 2012, 11: 92-96.
5. Gwaltney JM, Hendley JO, Simon G, Jordan WS Jr. Rhinovirus infections in an industrial population. Characteristics of illness and antibody response. JAMA, 1967, 202: 494–500.
6. Lopatin AS. Antibiotic therapy of acute inflammatory diseases of the paranasal sinuses. Consilium mediсum, 2003, 5 (4): 1-8.
7. Ryazantsev SV. Acute sinusitis. Approaches to therapy. Methodological guidelines. M., 2003. 16 p.
8. Little DR, Mann BL, Godbout CJ. How family Phisitians distinguish acute sinusitis from upper respiratory tract infections: a retrospective analysis. J Am Board Fam Pract, 2000, 13: 101–106.
9. Strachunsky LS, Tarasov AA, Kryukov AI. The causative pathogens of acute bacterial rhinosinusitis. Results of SSSR multicenter microbiological study. Klinicheskaya Mikrobiologiya i Antimikrobnaya Khimioterapiya, 2005, 7 (4): 337-349.
10. Hadley JA, Pfaller MA. Oral beta-lactams in the treatment of acute bacterial rhinosinusitis. Diagn Microbiol Infect Dis, 2007, 57(3): 47-54.
11. Brown T. Antibiotics May Not Be Needed for Acute Rhinosinusitis. Medscape Education Clinical Briefs, 2012. JAMA. 2012, 307: 685-692.
12. Rybak MJ. Increased bacterial resistance: PROTEKT US -- an update. The Annals of pharmacotherapy, 2004, 38(9 Suppl): 8-13.
13. Sidorenko SV. Trends in antibiotic resistance among community-acquired infection pathogens on the territory of the Russian Federation. Consilium Medicum, 2007, 9 (1).
14. Sahm DF, Benninger MS, Evangelista AT. Antimicrobial resistance trends among sinus isolates of Streptococcus pneumoniae in the United States (2001–2005). Otolaryngol Head Neck Surg, 2007, 136(3): 385–389.
15. Hsueh PR, Huang WK, Shyr J. Multicenter surveillance of antimicrobial resistance of Streptococcus pyogenes, Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis to 14 oral antibiotics. J Formos Med Assoc, 2004, 103(9): 664–670.
16. European Antimicrobial Resistance Surveillance Network (EARS-Net). EARSS Annual Report, 2008. http://www.ecdc.europa. eu/en/activities/surveillance/EARS-et/ Documents/2008_EARSS_Annual_Report.pdf.
17. Gracia M, Diaz C, Coronel P. Antimicrobial susceptibility of Haemophilus influenzae and Moraxella catarrhalis isolates in eight Central, East and Baltic European countries in 2005–06: results of the Cefditoren Surveillance Study. J Antimicrob Chemother, 2008, 61(5): 1180–1181.
18. Kozlov RS, Sivaya OV, Krechikova OI. Dynamics of Streptococcus pneumoniae resistance to antibiotics in Russia for the period 1999-2009. (Results of Pegasus multicenter prospective study). Klin. Mikrobiol. Antimikrob. Khimioter. 2010, 12 (4): 329-341.
19. Garbutt JM, Banister C, Spitznagel E, Piccirillo JF. Amoxicillin for acute rhinosinusitis: a ran-domized controlled trial. JAMA, 2012, 307(7): 685–692.
20. Ryazantsev SV. Acute sinusitis. Approaches to therapy. Methodological guidelines. M., 2003, 16.
21. Ryazantsev SV. Principles of ethiopathogenetic therapy for acute sinusitis. Methodical guidelines. St. Petersburg, 2013, 40 p.
22. Guo R, Peter H Canter, Edzard Ernst. Herbal medicines for the treatment of rhinosinusitis: A systematic review. Otolaryngology – Head and Neck Surgery, 2006, 135(4): 496-506.
23. Systematic review of clinical data with BNO-101 (Sinupret) in the treatment of sinusitis.
24. Melzer J, Saller R, Schapowal A, Brignoli R. Systematic Review of Clinical Data with BNO-101 (Sinupret®) in the Treatment of Sinusitis. Forsch Komplementä rmed, 2006, 13: 78–87.
25. Rossi A, Dehm F, Kiesselbach Ch, Haunschild J, Sautebin L, Werz O. The novel Sinupret® dry extract exhibits anti-inflammatory effectiveness in vivo. Fitoterapia, 2012, 83(4): 715-720.
Review
For citations:
Kochetkov PA, Mokoyan ZT. Complex therapy of acute bacterial rinosinusis. Meditsinskiy sovet = Medical Council. 2018;(8):16-19. (In Russ.) https://doi.org/10.21518/2079-701X-2018-8-16-19
Views:
705
Email this article 